ProMIS Neurosciences Inc PMN

All the marbles

[goldtech]

The global alzheimer's therapeutics market size was valued at USD 4.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 19.99% from 2023 to 2030. The rising prevalence of Alzheimer's Disease (AD) and approval of disease-modifying therapies are expected to fuel market growth.

So to sound like a broken record and to appeal to your sense of greed, if and I do mean if you show significant efficacy with minimal side effects, then you beat all the majors in this field and will take off on one of musks rockets. We will have an indication sometime in June, but our contracted CRO will be able to tell us after a month or so of dosing the first cohort. Gut wrenching times ahead and if this works all out other antibodies will get fast tracked.

[FarmerBetsy]

Goldtech doesn't work that way, results are blinded and even if they have 6 month results the clock doesn't start untill full enrollment then 6 months unless they have 100 ready to go which is not a consiistent practice with other companies. . Looking at a minimun of a year for interim results then up to 2 years for phase 1 results.  Fair to say with them after all these years not

[goldtech]

Sorry but you are wrong and the tranche A warrants are predicated on results that are either good or not and Warma has stated they will show efficacy in about 6 months of dosing the first cohort. I believe they will actually know before as patients themselves will be tested on an ongoing basis and certainly the scans will either show an increase of oligomers or a decrease and cognitive tests will

[FarmerBetsy]

i'll get you the facts! Who did the extensive BLOOD TESTING in phase 1 ? Was it Promis?  All the marbles without any licensing of any programs confirm tney don't have credibility with Big Pharma just hot air. The Boston group that has invested pocket change is set up for an easy exit just a couple of rumors easily recover their investment with a great return.